home / stock / xrtx:cc / xrtx:cc news

XRTX:CC News and Press, Xortx Therapeutics Inc. From 08/04/22

Stock Information
Company Name: Xortx Therapeutics Inc.
Stock Symbol: XRTX:CC
Market: TSXVC
Website: xortx.com
Menu
XRTX:CC XRTX:CC Quote XRTX:CC Short XRTX:CC News XRTX:CC Articles XRTX:CC Message Board
Get XRTX:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
XRTX:CC - XORTX Announces Pre-Phase 3 Meeting Date with US Food and Drug Administration

CALGARY, Alberta, Aug. 04, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ...
XRTX:CC - XORTX Reports Annual & Special Meeting Results

CALGARY, Alberta, July 22, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ...

XRTX:CC - XORTX Announces Submission to European Medicines Agency

CALGARY, Alberta, July 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, ann...

XRTX:CC - XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial

CALGARY, Alberta, July 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ...
XRTX:CC - XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)

CALGARY, Alberta, July 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ...

XRTX:CC - XORTX Announces "Fireside Chat" with XORTX CEO

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ...

XRTX:CC - XORTX to Present at BIO International Convention 2022

CALGARY, Alberta, June 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ...
XRTX:CC - XORTX to Present at LD Micro Invitational 2022

CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ...

XRTX:CC - XORTX to Present at H. C. Wainwright Global Investment Conference 2022

CALGARY, Alberta, May 25, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is please...

XRTX:CC - XORTX Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease

● FDA Provides All Clear Notification for IND and Bridging Pharmacokinetics Study ● CALGARY, Alberta, May 05, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical stage pharma...
Previous 10 Next 10